Nomegestrol Acetate

Summary

Nomegestrol Acetate (CHEMBL1476022) is an approved small molecule; indicated across 4 conditions including multiple sclerosis and polycystic ovary syndrome.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 4 conditions
• Clinical trials: 5
• Chemistry: 370.5 Da · C23H30O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1476022
Name	Nomegestrol Acetate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	91668
Molecular formula	C23H30O4
Molecular weight	370.5
InChIKey	IIVBFTNIGYRNQY-YQLZSBIMSA-N

SMILES: CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@H]4C1=CC(=O)CC4

IUPAC name: [(8S,9S,10R,13S,14S,17R)-17-acetyl-6,13-dimethyl-3-oxo-1,2,8,9,10,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate

Also known as: Ioa, Nomac, Nomegestrol acetate, TX 066, TX-066, Zoely, SID56463139, NOMEGESTROL ACETATE, NOMEGESTROL-ACETATE, nomegestrol-acetate, nomegestrol acetate

Parent form; salt/anhydrous children: CHEMBL2105722

Patent coverage: 521 distinct patent families (2,026 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Androgen receptor, Beta-lactamase, Glucocorticoid receptor, Progesterone receptor, 3’,5’-cyclic-AMP phosphodiesterase 4D, Gamma-aminobutyric acid receptor subunit alpha-1.

Bioactivity

ChEMBL activities: 6 potent at pChembl ≥ 5 of 8 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PGR	8.52	AC50	3	nM	CHEMBL_ACT_25204423
AR	7.7	AC50	20	nM	CHEMBL_ACT_25203490
PGR	7.55	AC50	28	nM	CHEMBL_ACT_25223043
NR3C1	7.17	AC50	67	nM	CHEMBL_ACT_25175850
P62813	5.6	AC50	2500	nM	CHEMBL_ACT_25130602
P62813	5.36	AC50	4400	nM	CHEMBL_ACT_25207966

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
multiple sclerosis	3	MONDO:0005301	MONDO:0005301
polycystic ovary syndrome	1	MONDO:0008487	EFO:0000660

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE4	2
PHASE3	1
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03077555	PHASE4	COMPLETED	Ovulation and Follicular Development Associated With Mid Follicular Phase Initiation of Combined Hormonal Contraception
NCT06316219	PHASE4	COMPLETED	The Use of Nomegestrol Acetate/Estradiol in Random Start Rapid Endometrial Preparation
NCT00127075	PHASE3	UNKNOWN	POPART’MUS: Prevention of Post Partum Relapses With Progestin and Estradiol in Multiple Sclerosis
NCT01361958	PHASE2	COMPLETED	Minimal Effective Dose of Nomegestrol Acetate Inhibiting the Ovulation in Women Receiving Estradiol
NCT01603745	PHASE1	UNKNOWN	Effects of Drospirenone-ethinylestradiol and/or NOMAC-valerate Estradiol on Cardiovascular Risk in Women With Polycystic Ovary Syndrome

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).